CDKN2A and glioblastoma: Liu et al. showed that CDKN2A/B homozygous deletion is a poor prognostic marker for IDH- and TERTp-wild-type GBMs, which is consistent with our findings.23 To date, the prognostic value of PTEN alterations in GBM remains controversial.